UNSPSC 51281819: Epirubicin hydrochloride

This classification denotes an antineoplastic antibiotic with the molecular formula C27H29NO11.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22966TX7J5, chemically known as 5,12-naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8s-cis)- but more generally known as epirubicin hydrochloride, which bears US NIH Compound Identifier 32874.

UNSPSC 51281819 Epirubicin hydrochloride, a Commodity code, shows a significant mismatch between its nominal scope and the actual work being solicited under it in recent state and local procurement. While the code identifies a specific chemotherapy drug, the recent opportunities tagged to it involve naloxone procurement, direct-to-manufacturer pharmaceutical programs, medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals through cooperative purchasing. None of these solicitations address epirubicin hydrochloride specifically. The code shows little relevant recent activity aligned with its stated pharmaceutical commodity.

State and local issuing bodies across Florida, Texas, Minnesota, and Oregon have posted opportunities under this code that reflect broader pharmaceutical and medical supply procurement — including Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a 5% small local business enterprise discount and response due March 13, 2026; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026). The tagging of these opportunities under a code for epirubicin hydrochloride appears to reflect data quality or classification issues in the source system rather than intentional procurement of that specific drug. Firms evaluating this code should verify actual solicitation scope in the underlying RFP or IFB documents before pursuing opportunities.